Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease

CNS Neuroscience and Therapeutics

Volumn 14, Issue 1, 2008, Pages 83-93

  Lees, Andrew J ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Catechol O methyltransferase; Entacapone; Meta analysis; Motor fluctuations Parkinson's disease; Tolcapone

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ENTACAPONE; PLACEBO; TOLCAPONE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; LIVER ENZYME;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FOLLOW UP; FOOD DRUG INTERACTION; HEPATITIS; HUMAN; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; CLINICAL PRACTICE; DRUG DOSE REDUCTION; DRUG POTENCY; FOOD AND DRUG ADMINISTRATION; LIVER CELL DAMAGE; LIVER FUNCTION; LIVER TOXICITY; PATIENT SAFETY; RECOMMENDED DRUG DOSE;

AGED; ANTIPARKINSON AGENTS; BENZOPHENONES; CATECHOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; NITRILES; NITROPHENOLS; PARKINSON DISEASE;

EID: 47149100706     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2007.00035.x     Document Type: Review

References (41)

1. Adler CH, Singer C, O'Brien C, Hauser RA, Lew MF, Marek KL, Dorflinger E, Pedder S, Deptula D, Yoo K (1998) Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 55 : 1089 1095.
2. Baas H, Beiske AG, Ghika J, Jackson M, Oertel WH, Poewe W, Ransmayr G (1997) Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating Parkinsonian patients. J Neurol Neurosurg Psychiatry 63 : 421 428.
3. Berlin JA, Laird NM, Sacks HS, Chalmers TC (1989) A comparison of statistical methods for combining event rates from clinical trials. Stat Med 8 : 141 151.
4. Borges N (2005) Tolcapone in Parkinson's disease: Liver toxicity and clinical efficacy. Expert Opin Drug Saf 4 : 69 73.
5. Brooks DJ, Sagar H (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 74 : 1071 1079.
6. Cochrane Collaboration (2007) http://www.cochrane.org. Accessed: Aug. 10, 2007.
7. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 (2005) In : The Cochrane library. Chichester, UK, John Wiley & Sons.
8. Comtan® (entacapone) tablets [package insert] (2000) East Hanover, NJ, USA, Novartis Pharmaceuticals Corporation.
9. Deane KHO, Spieker S, Clarke CE (2004) Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev Issue 4, Art. No.: CD004554. DOI: 10.1002/14651858.CD004554. pub2".
10. Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E (1997) Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study. Tolcapone in Parkinson's disease study group II (TIPS II). Mov Disord 12 : 928 934.
11. Factor SA, Molho ES, Feustel PJ, Brown DL, Evans SM (2001) Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease. Clin Neuropharmacol 24 : 295 299.
12. Fénelon G, Giménez-Roldán S, Montastruc JL, Bermejo F, Durif F, Bourdeix I, Péré JJ, Galiano L, Schadrack J (2003) Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm 110 : 239 251.
13. Forsberg M, Lehtonen M, Heikkinen M, Savolainen J, Jarvinen T, Mannisto PT (2003) Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: A comparative study in the rat. J Pharmacol Exp Ther 304 : 498 506.
14. Gordin A, Kaakkola S, Teravainen H (2004) Clinical advantages of COMT inhibition with entacapone - a review. J Neural Transm 111 : 1343 1363.
15. Im JH, Jeon BS, Lee MS, Lee WY, Kim JW, Lee MC (2002) A multicentre, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson's disease experiencing end-of-dose deterioration [abstract P83]. Mov Disord 17 : S40.
16. Jorga K, Fotteler B, Sedek G, Nielsen T, Aitken J (1998a) The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 245 : 223 230.
17. Jorga KM, Fotteler B, Heizmann P, Zurcher G (1998b) Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy. Eur J Clin Pharmacol 54 : 443 447.
18. Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59 : 1233 1250.
19. Keating GM, Lyseng-Williamson KA (2005) Tolcapone: A review of its use in the management of Parkinson's disease. CNS Drugs 19 : 165 184.
20. Kurth MC, Adler CH, Hilaire MS, Singer C, Waters C, LeWitt P, Chernik DA, Dorflinger EE, Yoo K (1997) Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial. Neurology 48 : 81 87.
21. Lees AJ, Ratziu V, Tolosa E, Oertel WH (2007) Safety and tolerability of adjunctive tolcapone therapy in early Parkinson's disease patients. J Neurol Neurosurg Psychiatry 78 : 944 948.
22. Lew MF, Kricorian G (2007) Results from a 2-year centralized tolcapone liver enzyme monitoring program. Clin Neuropharmacol 30 : 281 286.
23. Myllyla VV, Jackson M, Larsen JP, Baas H (1997) Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with "wearing-off" phenomenon: A multicentre, double-blind, randomised, placebo-controlled trial. Eur J Neurol 4 : 333 341.
24. Myllyla VV, Kultalahti ER, Haapaniemi H, Leinonen M (2001) Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 8 : 53 60.
25. National Institute for Health and Clinical Excellence (2006) Parkinson's disease: Diagnosis and management in primary and secondary care In : NICE clinical guideline 35. London, UK : National Collaborating Centre for Chronic Conditions.
26. Olanow CW, Tasmar Advisory Panel (2000) Tolcapone and hepatotoxic effects. Arch Neurol 57 : 263 267.
27. Onofrj M, Thomas A, Iacono D, Di Iorio A, Bonanni L (2001) Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur Neurol 46 : 11 16.
28. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ (2006) Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 : 983 995.
29. Parashos SA, Wielinski CL, Kern JA (2004) Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. Clin Neuropharmacol 27 : 119 123.
30. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42 : 747 755.
31. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105 : 245 255.
32. Prescrire Editorial Staff (2006) Tolcapone: New drug. In Parkinson's disease: Unacceptable risk of severe hepatitis. Prescrire Int 15 : 54 57.
33. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S (1997) Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicenter trial. Neurology 49 : 1066 1071.
34. Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51 : 1309 1314.
35. Ruottinen HM, Rinne UK (1996) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19 : 283 296.
36. Tasmar® (tolcapone) Prescribing Information (2005) In : Physicians' desk reference. Montvale, NJ : Thompson PDR, 59th ed.
37. Tasmar® (tolcapone) Prescribing Information (2006) In : Physicians' desk reference. Montvale, NJ : Thompson PDR, 60th ed.
38. Tasmar® (tolcapone) tablets [package insert] (2006) Aliso Viejo, CA, USA, Valeant Pharmaceuticals International.
39. Tasmar® Summary of Product Characteristics (2006) http://www.emea.eu.int/humandocs/PDFs/EPAR/tasmar/H-132-PI-en.pdf. Accessed: Oct. 10, 2007.
40. The Entacapone to Tolcapone Switch Study Investigators (2007) Entacapone to tolcapone switch: Multicenter double-blind, randomized, active-controlled trial in advanced Parkinson's disease. Mov Disord 22 : 14 19.
41. Watts R, Kricorian G (2005) Evaluation of liver-related adverse events with tolcapone: A review of 7 years of worldwide safety data [abstract P400]. Mov Disord 20 Suppl 10 : S118.